Ishigami, Yuma http://orcid.org/0000-0002-5704-291X
Wong, Mandy S.
Martí-Gómez, Carlos
Ayaz, Andalus
Kooshkbaghi, Mahdi
Hanson, Sonya M. http://orcid.org/0000-0001-8960-5353
McCandlish, David M. http://orcid.org/0009-0006-1474-0407
Krainer, Adrian R. http://orcid.org/0000-0001-9024-9501
Kinney, Justin B. http://orcid.org/0000-0003-1897-3778
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R37 GM42699, R35 GM133777, R01 HG011787, P30 CA045508, S10 OD020122)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (S10 OD28632)
MEXT | Japan Society for the Promotion of Science (Overseas Research Fellowship to Yuma Ishigami)
Alfred P. Sloan Foundation (Fellowship to David McCandlish)
Article History
Received: 22 February 2023
Accepted: 10 February 2024
First Online: 29 February 2024
Competing interests
: A.R.K. is an inventor on issued nusinersen patents licensed by CSHL to Ionis Pharmaceuticals and Biogen; an inventor on an issued patent for familial dysautonomia ASOs; a co-founder, Director, Chair of the SAB, and shareholder of Stoke Pharmaceuticals; a paid consultant for Biogen; a collaborator of Ionis Pharmaceuticals; and a member of the SABs and shareholder of Skyhawk Pharmaceuticals, Envisagenics, Autoimmunity BioSolutions, and assembl.cns. Other authors declare no competing interests.